Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of Immune-mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Colorectal Cancer in Individuals With Familial Adenomatous Polyposis, Based on Analysis of the Danish Polyposis Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Experience from a COVID-19 first-line referral clinic in Greater Copenhagen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Normative data for eight verbal fluency measures in older Danish adults

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • International PSC Study Group (IPSCSG)
Vis graf over relationer

BACKGROUND & AIMS: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD.

METHODS: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy.

RESULTS: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P = .035). Factors associated with lower ALP were normal ALP at baseline (P < .01), treatment with adalimumab (P = .090), and treatment in Europe (P = .083).

CONCLUSIONS: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.

OriginalsprogEngelsk
TidsskriftClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Vol/bind18
Udgave nummer10
Sider (fra-til)2295-2304.e2
ISSN1542-3565
DOI
StatusUdgivet - 1 sep. 2020

Bibliografisk note

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

ID: 59370010